ReviewNanoscale advances2021
Recent advances in phase change material based nanoplatforms for cancer therapy.
Review in Nanoscale advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer.Lipids in health and disease · 2025Review
- Highly stable and near-infrared responsive phase change materials for targeted enzyme delivery toward cancer therapy.Materials today. Bio · 2024Article
- Carbon-Enhanced Hydrated Salt Phase Change Materials for Thermal Management Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Tumor microenvironment-activated theranostic nanoreactor for NIR-II Photoacoustic imaging-guided tumor-specific photothermal therapy.Fundamental research · 2024Article
- In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms.Exploration (Beijing, China) · 2023Review
- Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies.Nanoscale advances · 2023Review
- Iron-Based Hollow Nanoplatforms for Cancer Imaging and Theranostics.Nanomaterials (Basel, Switzerland) · 2022Review
- Recent advances in smart nanoplatforms for tumor non-interventional embolization therapy.Journal of nanobiotechnology · 2022Review
- Lasered Graphene Microheaters Modified with Phase-Change Composites: New Approach to Smart Patch Drug Delivery.Micromachines · 2022Article
- Thermally switchable, crystallizable oil and silicone composite adhesives for skin-interfaced wearable devices.Science advances · 2022Article
- Recent advances of cancer chemodynamic therapy based on Fenton/Fenton-like chemistry.Chemical science · 2022Review
- Phase-change materials-based platforms for biomedicine.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has become a severe threat to human life due to its high mortality and metastatic rate. Effective inhibition and killing of cancer cells using chemotherapeutic drugs have been a promising means in clinical cancer therapy. However, the low selectivity, drug-resistance, uncontrollability and serious side effects of chemotherapy significantly limit its further development. There is an urgent need for new treatment strategies to compensate for deficiencies inherent in chemotherapy alone. A growing body of research shows that combined treatment strategies have the potential to overcome this dilemma by achieving significantly enhanced synergistic effects and reduced side effects. Emerging phase change materials (PCMs) create an ideal nanoplatform for cancer combination therapy due to their universal loading properties, stable and temperature-responsive phase transition capability, and excellent natural biocompatibility/biodegradability. The release of therapeutic agents can be precisely controlled through external, non-intrusive stimuli (such as NIR light and ultrasound), avoiding systemic toxicity associated with conventional chemotherapy. Herein, the construction methods and design principles of PCM-based nanoplatforms serving as strict gatekeeper and smart payload delivery systems are discussed in detail. Moreover, the advantages and disadvantages of these nanoplatforms are provided. A suitable discussion and perspective of the remaining challenges and future opportunities for PCM-based nanoplatforms in cancer treatment are also given in conclusion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.